title: Synthetic cannabis and respiratory depression.
abstract: In recent years, synthetic cannabis use has been increasing in appeal among adolescents, and its use is now at a 30 year peak among high school seniors. The constituents of synthetic cannabis are difficult to monitor, given the drug's easy accessibility. Currently, 40 U.S. states have banned the distribution and use of some known synthetic cannabinoids, and have included these drugs in the Schedule I category. The depressive respiratory effect in humans caused by synthetic cannabis inhalation has not been thoroughly investigated in the medical literature. We are the first to report, to our knowledge, two cases of self-reported synthetic cannabis use leading to respiratory depression and necessary intubation.
authors.affiliation: Department of Psychiatry, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, NJ 08854, USA.
authors.forename: Felecia N
authors.initials: FN
authors.lastname: Jinwala
authors.forename: Mayank
authors.initials: M
authors.lastname: Gupta
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D002188:Cannabis / Q000009:adverse effects* / Q000737:chemistry; D006801:Humans; D013287:Illicit Drugs / Q000009:adverse effects* / Q000138:chemical synthesis; D007442:Intubation, Intratracheal; D008297:Male; D012131:Respiratory Insufficiency / Q000139:chemically induced*; D055815:Young Adult
chemical_list: D013287:Illicit Drugs